NASDAQ:UROV Urovant Sciences (UROV) Stock Price, News & Analysis → Urgent: Protect Your Investments from a Chinese Invasion (From Behind the Markets) (Ad) Free UROV Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$16.24▼$16.2450-Day Range$16.19▼$16.2452-Week Range$7.15▼$16.26VolumeN/AAverage Volume114,469 shsMarket Capitalization$531.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Urovant Sciences alerts: Email Address Ad Crypto 101 MediaAltcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!) About Urovant Sciences Stock (NASDAQ:UROV)Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.Read More Ad WealthPressA lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. Click here to jump in on the next one UROV Stock News HeadlinesMarch 26, 2024 | finance.yahoo.comA2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of DirectorsDecember 6, 2023 | finance.yahoo.comPetauri™ Elects William Fleming and James Robinson to Its Board of DirectorsMarch 28, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.October 4, 2023 | finance.yahoo.comPM360 Announces 2023 Trailblazer Award WinnersSeptember 11, 2023 | finance.yahoo.comEledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of DirectorsJuly 31, 2023 | finance.yahoo.comCNVCF - BioHarvest Sciences Inc.July 25, 2023 | businesswire.comUroGen Pharma Announces the Appointment of James Robinson to its Board of DirectorsJuly 20, 2023 | benzinga.comBenign Prostatic Hyperplasia Therapeutics Market Size Predictions suggest a rise of 5.1% CAGR, to reach value of USD 12.9 Billion by 2032March 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.June 24, 2023 | npr.orgKPCW Cool Science RadioJune 9, 2023 | uk.finance.yahoo.comOveractive Bladder Treatment Global Market Report 2023May 22, 2023 | finanznachrichten.dePierre Fabre announces start of EU marketing authorization application procedure for Vibegron in overactive bladderMay 3, 2023 | bizjournals.comThree Japanese pharma subsidiaries to lay off 223 in MarlboroughMarch 28, 2023 | finance.yahoo.comOveractive Bladder Market to Grow Rapidly at a Considerable CAGR During the Forecast Period (2023–2032) | DelveInsightFebruary 19, 2023 | marketwatch.comDrugs for Enuresis Market 2023: Growth by 2029 Top Players with OpportunitiesJanuary 19, 2023 | technews.tmcnet.comUrovant Sciences® Announces Collaboration with Holly Robinson Peete to Help Raise Awareness for Overactive Bladder and Treatment OptionsJanuary 16, 2023 | marketwatch.comDrugs for Enuresis Market Share From 2023 To 2029 And Unlimited Opportunities for New Companies and Latest DevelopmentsDecember 21, 2022 | msn.comHow To Deal With An Overactive Bladder If You're Traveling Long Distance Over The HolidaysDecember 20, 2022 | seekingalpha.comRoivant Sciences: A Solid Year Of Progress And Good Prospects For 2023October 27, 2022 | finance.yahoo.comUrovant Sciences Announces Publication of Pharmacokinetic Data on GEMTESA® (Vibegron 75mg) Administered as an Intact or Crushed TabletOctober 4, 2022 | seekingalpha.comMyovant: Sumitomo Bid Is A Head Scratcher, Where Is The Value?September 30, 2022 | financialpost.com'I lose money every time I leave the house': Inflation complicates back-to-office pushSeptember 26, 2022 | investopedia.comSocial Science: What It Is and the 5 Major BranchesSeptember 13, 2022 | usnews.comBest Global Universities for Computer ScienceSeptember 10, 2022 | npr.orgScience FridaySeptember 8, 2022 | cnbc.comHealth and ScienceSeptember 7, 2022 | finanznachrichten.deUrovant Sciences, Inc.: Urovant Sciences Named 17th on the List of Fortune Best Workplaces in BioPharma (2022)See More Headlines Receive UROV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Urovant Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/11/2021Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:UROV CUSIPN/A CIK1740547 Webwww.urovant.com Phone44-0-20-7400-3347FaxN/AEmployees70Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-146,740,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-162.90% Debt Debt-to-Equity RatioN/A Current Ratio2.91 Quick Ratio2.91 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.90) per share Price / Book-8.55Miscellaneous Outstanding Shares32,743,000Free FloatN/AMarket Cap$531.75 million OptionableNot Optionable Beta2.36 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. James A. Robinson Jr. (Age 50)Pres, CEO & Director Comp: $1.07MMr. Ajay Bansal (Age 59)CFO & Sr. VP of Bus. Devel. Comp: $558.34kDr. Cornelia Haag-Molkenteller M.D. (Age 62)Ph.D., Chief Medical Officer of USI Comp: $629.79kMs. Christine G. Ocampo (Age 49)Chief Accounting Officer & Sr. VP Ryan KubotaExec. Director of Investor RelationsMr. Bryan E. Smith (Age 42)Gen. Counsel Dr. David HovlandSr. VP of Global Regulatory AffairsMr. Kenton StewartSr. VP of Market AccessMore ExecutivesKey CompetitorsBiomea FusionNASDAQ:BMEAMersana TherapeuticsNASDAQ:MRSNPhibro Animal HealthNASDAQ:PAHCIGM BiosciencesNASDAQ:IGMSALX OncologyNASDAQ:ALXOView All Competitors UROV Stock Analysis - Frequently Asked Questions How were Urovant Sciences' earnings last quarter? Urovant Sciences Ltd. (NASDAQ:UROV) announced its quarterly earnings data on Thursday, February, 11th. The company reported ($1.46) EPS for the quarter, beating analysts' consensus estimates of ($1.59) by $0.13. What other stocks do shareholders of Urovant Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Urovant Sciences investors own include Fulcrum Therapeutics (FULC), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), AVEO Pharmaceuticals (AVEO), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Provention Bio (PRVB), SCYNEXIS (SCYX) and Xeris Biopharma (XERS). When did Urovant Sciences IPO? Urovant Sciences (UROV) raised $150 million in an initial public offering on Thursday, September 27th 2018. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and Cowen acted as the underwriters for the IPO. This page (NASDAQ:UROV) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research Advisory Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Urovant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.